Research programme: respiratory syncytial virus vaccine - Pevion Biotech

Drug Profile

Research programme: respiratory syncytial virus vaccine - Pevion Biotech

Alternative Names: PEV 4; RSV vaccine - Pevion Biotech

Latest Information Update: 06 May 2010

Price : $50

At a glance

  • Originator Pevion Biotech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 26 Apr 2010 Pharmacodynamics and immunogenicity data from a Preclinical trial in Respiratory syncytial virus infections released by Pevion Biotech
  • 05 Feb 2007 Preclinical development is ongoing
  • 25 Feb 2005 Preclinical trials in Respiratory syncytial virus infections in Europe (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top